Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 clients • 5 examiners • 3 art units • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sheppard Mullin Richter & Hampton LLP-Ionis Pharm operates in the Biotechnology & Pharmaceuticals technology area. The firm has a total of 14699 career applications, resulting in a resolved allowance rate pct of 87.15. There are currently 3 pending office actions. The 14699 career applications show the firm's experience in the biotechnology sector.
The average office actions per allowance for this profile is 3.19. This figure helps practitioners understand the typical prosecution cycle for Biotechnology & Pharmaceuticals patents. The 87.15 resolved allowance rate pct indicates the track record of success for the 14699 career applications filed. With only 3 pending office actions, the current active docket for this specific profile is focused. These metrics provide a comprehensive view of the firm's historical performance and its current activity level in its primary technical field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.0% | +18.0% |
| GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1 | 41.4% | +58.4% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 56.3% | +40.2% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.6% |
| ZARA, JANE J | 1 | 71.0% | +16.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18247311 | COMPOUNDS FOR MODULATING CHMP7 | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| 17508516 | COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION | ZARA, JANE J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18457941 | MODULATORS OF PNPLA3 EXPRESSION | POLIAKOVA-GEORGAN, EKATERINA | — |
| 18247311 | COMPOUNDS FOR MODULATING CHMP7 | GOMEZ RODRIGUEZ, JULIO WASHINGTON | — |
| 18245609 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTISENSE OLIGONUCLEOTIDE FOR ORAL ADMINISTRATION | DACE DENITO, ALEXANDRA GERALDINE | — |
| 17508516 | COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION | ZARA, JANE J | — |
| Client (Assignee) | Pending OAs |
|---|---|
| IONIS PHARMACEUTICALS, INC. | 4 |
| Ionis Pharmceuticals, Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1637 | 3 |
| 1636 | 1 |
| 1600 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18457941 | MODULATORS OF PNPLA3 EXPRESSION | Ionis Pharmaceuticals, Inc. | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §112DPOther | Non-Final OA | — | Pending | Aug 29, 2023 |
| 18247311 | COMPOUNDS FOR MODULATING CHMP7 | Ionis Pharmaceuticals, Inc. | GOMEZ RODRIGUEZ, JULIO WASHINGTON | 1637 | §102§103§112 | Non-Final OA | — | Pending | Mar 30, 2023 |
| 18245609 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTISENSE OLIGONUCLEOTIDE FOR ORAL ADMINISTRATION | Ionis Pharmceuticals, Inc. | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Mar 16, 2023 |
| 17635096 | MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | Ionis Pharmaceuticals, Inc. | VIVLEMORE, TRACY ANN | 1600 | §103 | Non-Final OA | — | Pending | Feb 14, 2022 |
| 17508516 | COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION | Ionis Pharmaceuticals, Inc. | ZARA, JANE J | 1637 | §102§103§112 | Non-Final OA | — | Pending | Oct 22, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial